Skip to main content
德源药业 logo

德源药业 — Investor Relations & Filings

Ticker · 920735 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 569 across all filing types
Latest filing 2022-03-29 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920735

About 德源药业

http://www.pharmdy.com

Deyuan Pharmaceutical specializes in the research, development, production, and commercialization of therapeutic drug preparations. The company focuses on chronic disease management, particularly in the fields of endocrinology and cardiovascular health. Its core product line includes treatments for diabetes, hypertension, and hyperlipidemia, featuring medications such as Metformin Hydrochloride sustained-release tablets, Pioglitazone Hydrochloride, and Valsartan. The organization emphasizes technological innovation and maintains rigorous quality control standards across its manufacturing processes. By leveraging advanced formulation technologies, the company develops high-efficacy pharmaceutical solutions aimed at addressing the long-term needs of patients with metabolic and circulatory disorders.

Recent filings

Filing Released Lang Actions
续聘会计师事务所公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the company's intention to renew the appointment of an accounting firm (auditor) for the 2022 fiscal year. It details the auditor's background, independence, audit fees, and the approval process by the board and audit committee. There is no actual audit report or financial statements included, nor is there a detailed audit opinion or results. The document is a formal announcement about the auditor appointment process, not the audit report itself. The document length is 3746 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this fits best under the category of Audit Report / Information (AR) as it relates to audit information but is not a full annual report or audit report itself. However, since it is specifically about the appointment of the auditor and not the audit report, it is best classified as AR (Audit Report / Information). FY 2022
2022-03-29 Chinese
关于治理专项自查及规范活动相关情况的报告
Governance Information Classification · 95% confidence The document is a detailed report on corporate governance self-inspection and compliance activities by Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes information on company control, internal systems, board and management structure, decision-making processes, and governance constraints. The content focuses on governance practices, internal controls, board and committee composition, and compliance with relevant laws and regulations. There is no financial data, earnings information, or audit results presented. The document is not an announcement of a report but the report itself on governance matters. Therefore, it fits best under the category of Governance Information (CGR). The document length (6046 characters) supports it being a substantive report rather than a brief announcement.
2022-03-29 Chinese
募集资金年度存放与使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金年度存放与使用情况鉴证报告" which translates to "Annual Verification Report on the Storage and Use of Raised Funds." It is issued by an accounting firm (天健会计师事务所) and includes detailed information about the company's fundraising activities, the use and management of raised funds, and verification of these by auditors. The document references compliance with the Beijing Stock Exchange listing rules and includes audit report numbers and signatures of certified accountants. The content is focused on the verification and audit of the company's use of capital raised through stock issuance, rather than a full annual report or earnings release. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial matters, excluding full annual reports. The document is substantive and detailed, not a mere announcement or certification letter, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the best classification is AR with high confidence.
2022-03-29 Chinese
开源证券股份有限公司关于江苏德源药业股份有限公司2021年年度募集资金存放与实际使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from a securities company acting as a sponsor, providing an audit opinion on the 2021 annual fundraising funds deposit and actual usage situation of Jiangsu Deyuan Pharmaceutical Co., Ltd. It includes detailed financial data on fundraising amounts, usage, balances, management, and changes in fund usage. The document references specific regulatory approvals, fundraising dates, and detailed financial tables. It is not a brief announcement or a certification letter but a substantive report on fundraising fund usage for a full fiscal year. This matches the characteristics of an Audit Report / Information (AR) filing, which covers audit opinions and detailed fund usage verification, distinct from a full Annual Report (10-K) or a simple announcement. Therefore, the classification is AR with high confidence.
2022-03-29 Chinese
独立董事关于第三届董事会第十一次会议相关事项的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a formal announcement from the independent directors of Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding their prior approval opinion on the proposal to reappoint the auditing firm Tianjian Accounting Firm for the 2022 fiscal year. It references the company's board meeting and legal compliance but does not contain any actual audit report or financial statements. The document is short (739 characters) and serves as an announcement of a board decision related to audit matters rather than the audit report itself. Therefore, it fits best under Audit Report / Information (AR) as it relates to audit firm appointment and audit-related matters, but is not a full annual report or audit report document. Confidence is high given the clear focus on audit firm reappointment and the nature of the content. FY 2021
2022-03-29 Chinese
关于以自有闲置资金进行委托理财的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Jiangsu Deyuan Pharmaceutical Co., Ltd. regarding the use of idle self-owned funds for entrusted financial management. It details the board meeting resolution, investment purpose, risk control measures, and the approval process. The document is a formal announcement about a capital management decision, specifically about investing idle funds in low-risk financial products. It does not contain financial statements, earnings data, or audit information. It is not a report but an announcement of a financing-related activity. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is short (1939 characters), and it is not a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2022-03-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.